AU5289899A - Transmucosal therapeutic system for administering sildenafil - Google Patents

Transmucosal therapeutic system for administering sildenafil

Info

Publication number
AU5289899A
AU5289899A AU52898/99A AU5289899A AU5289899A AU 5289899 A AU5289899 A AU 5289899A AU 52898/99 A AU52898/99 A AU 52898/99A AU 5289899 A AU5289899 A AU 5289899A AU 5289899 A AU5289899 A AU 5289899A
Authority
AU
Australia
Prior art keywords
therapeutic system
transmucosal therapeutic
sildenafil
administering
administering sildenafil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU52898/99A
Other languages
English (en)
Inventor
Thomas Strungmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hexal AG
Original Assignee
Hexal AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal AG filed Critical Hexal AG
Publication of AU5289899A publication Critical patent/AU5289899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU52898/99A 1998-07-31 1999-07-30 Transmucosal therapeutic system for administering sildenafil Abandoned AU5289899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19834506A DE19834506A1 (de) 1998-07-31 1998-07-31 Transmucosales therapeutisches System zur Anwendung von Sildenafil
DE19834506 1998-07-31
PCT/EP1999/005465 WO2000007597A1 (fr) 1998-07-31 1999-07-30 Systeme de traitement transmuqueux pour l'utilisation de sildenafil

Publications (1)

Publication Number Publication Date
AU5289899A true AU5289899A (en) 2000-02-28

Family

ID=7875940

Family Applications (1)

Application Number Title Priority Date Filing Date
AU52898/99A Abandoned AU5289899A (en) 1998-07-31 1999-07-30 Transmucosal therapeutic system for administering sildenafil

Country Status (3)

Country Link
AU (1) AU5289899A (fr)
DE (1) DE19834506A1 (fr)
WO (1) WO2000007597A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100463668C (zh) * 2005-05-09 2009-02-25 凌沛学 可逆性热凝胶化水性药物组合物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CA2391968A1 (fr) * 1999-11-18 2001-05-25 Natco Pharma Limited Composition pharmaceutique amelioree pour traiter la dyserection masculine
BRPI0003386B8 (pt) 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
CA2425539C (fr) * 2000-10-12 2007-04-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Monohydrate cristallin, procedes permettant sa preparation et son utilisation pour la preparation d'une composition pharmaceutique
EP1404336A1 (fr) * 2001-06-14 2004-04-07 Sampad Bhattacharya Compositions comprenant un inhibiteur de cgmp pde5 pour administration transdermique au tissu erectile du penis
US20060035905A1 (en) * 2004-02-06 2006-02-16 Becton, Dickinson And Company Formulations of phosphodiesterase 5 inhibitors and methods of use
GB0606234D0 (en) * 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
WO2008019106A1 (fr) * 2006-08-04 2008-02-14 Artesian Therapeutics, Inc. Méthodes et compositions pour le traitement d'hypertension pulmonaire utilisant une combinaison d'un agent bloquant de canal calcium et un inhibiteur de phosphodiestérase
US20100104624A1 (en) * 2008-06-11 2010-04-29 Peter Langecker Combination therapy using phosphodiesterase inhibitors
EP2575765B1 (fr) * 2010-06-07 2018-12-05 Suda Ltd Formulations pour pulvérisation orale et méthodes d'administration du citrate de sildénafil
US9186321B2 (en) 2011-12-05 2015-11-17 Suda Ltd. Oral spray formulations and methods for administration of sildenafil
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
CN1244119A (zh) * 1997-01-06 2000-02-09 辉瑞大药厂 迅速释放和掩蔽味觉的药物剂型
JPH10298062A (ja) * 1997-04-24 1998-11-10 Pfizer Pharmaceut Co Ltd 口腔内速溶型錠剤
ES2270517T3 (es) * 1997-05-19 2007-04-01 Zonagen, Inc. Terapia de combinacion para modular la respuesta sexual humana.
WO1999002161A1 (fr) * 1997-07-09 1999-01-21 Forssmann Wolf Georg Utilisation d'inhibiteurs de la phosphordiesterase dans le traitement de maladies de la prostate
US6656452B1 (en) * 1997-10-21 2003-12-02 The General Hospital Corporation Use of inhaled NO as anti-inflammatory agent
EP1027054A4 (fr) * 1997-10-28 2002-11-04 Vivus Inc Apport local d'inhibiteurs de phosphodiesterases, dans le traitement du dysfonctionnement erectile
EP1035833B1 (fr) * 1997-12-02 2005-08-31 Archimedes Development Limited Compositions pour administration nasale
GB9726343D0 (en) * 1997-12-13 1998-02-11 Auffret Anthony The use of excipients to accelerate freeze-drying
TW542719B (en) * 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100463668C (zh) * 2005-05-09 2009-02-25 凌沛学 可逆性热凝胶化水性药物组合物

Also Published As

Publication number Publication date
WO2000007597A1 (fr) 2000-02-17
DE19834506A1 (de) 2000-02-03

Similar Documents

Publication Publication Date Title
AU6558296A (en) Buccal delivery system for therapeutic agents
AU1618800A (en) Microporous drug delivery system
AU1225000A (en) Combined pharmaceutical estrogen-androgen-progestin
AU3387399A (en) Disposable anesthesia delivery system
AU1728797A (en) Comforter for delivering medicine
AU4551199A (en) Novel therapeutic agents for membrane transporters
AU1071200A (en) Systems for oral delivery
EP1061987A4 (fr) Dispositif servant a administrer un medicament
AU1101699A (en) Therapeutic pillow
AU1986099A (en) Device for inhaling medicament
AU3999699A (en) Targeted liposomal drug delivery system
AU8495998A (en) Improved dosage units
AU5289899A (en) Transmucosal therapeutic system for administering sildenafil
AU7454698A (en) Improvement in medicament administration system
AU6256600A (en) Wheelchair system
AU6436998A (en) Therapeutic uses for antioxidants
AU5092099A (en) Vibroacoustic delivery system
AU5836700A (en) Peptides for therapeutic use
AU4443599A (en) Therapeutic bed
AU1671997A (en) Drug delivery system using galactoxyloglucan
AU7449698A (en) Therapeutic agents for respiratory diseases
AU4416500A (en) Tomographic system
AU5093199A (en) Transdermal delivery system
AU4707599A (en) Denture system
AU2190301A (en) Ranging system

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase